<DOC>
	<DOCNO>NCT02985957</DOCNO>
	<brief_summary>The purpose study determine whether nivolumab plus ipilimumab preliminary evidence safety effectiveness treatment metastatic castration-resistant prostate cancer</brief_summary>
	<brief_title>A Study Evaluate Preliminary Safety Efficacy Nivolumab Plus Ipilimumab Men With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Metastatic , castrate resistant prostate cancer ( M1 National Comprehensive Cancer Network ( NCCN ) criterion ) Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Ongoing androgen deprivation therapy ( ADT ) Gonadotropinreleasing hormone ( GnRH ) analogue surgical/medical castration testosterone level ≤1.73nmol/L ( 50ng/dL ) Patients skeletal system symptom already medication strengthen bone allow start ˃28 day enrollment Bonedirected radiotherapy pelvic region ease pain painful bone metastasis allow 14 day Cancer spread liver brain Active , know , suspect autoimmune disease infection Prior treatment drug target T cell costimulation pathway ( checkpoint inhibitor ) Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>